CD19 및 CD22를 동시에 표적하는 이가위 Chimeric Antigen Receptors의 전임상 개발

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia2012 · 584 citations
2. 2Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases2011 · 223 citations
3. 3Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models2017 · 6 citations
4. 4TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy2013 · 459 citations
5. 5CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy2017 · 1,349 citations